Diagnostics
Oxford Immunotec Global PLC, or the Company, a global, high-growth diagnostics company, announced second quarter 2019 financial results.
Funding will finance further development and IVD-CE marking of the company’s first molecular POC (Point of Care) platform, based on Pulse Controlled Amplification (PCA) technology
The combined companies will have revenue drivers of two commercially available diagnostics tools, Cologuard and Oncotype DX.
hematologists and multiple myeloma patients in the UK will have access to Dutch developed diagnostic test MMprofilerTM with SKY92 algorithm through the diagnostic service provided by Everything Genetic Ltd. SkylineDx, the diagnostics company that developed the test, announced its collaboration with the UK based provider of a genetic testing service.
The academic hematology department of Erasmus Medical Center is globally the first hospital to offer every multiple myeloma patient an innovative diagnostic service that predicts the aggressiveness of the disease by measuring 92 genes in the cancer cells
For quite some time, the focus of the cause of Alzheimer’s disease was on beta-amyloid, a protein that accumulates in the brains of individuals with the disease and which appears to cause at least some of the damage that results in memory and cognition issues. There are other candidates, and research appears to be heating up on the role of inflammation.
Todos Medical Ltd., a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer’s disease, announced that it has launched a roadshow for a public offering of up to $7,000,000 of units.
Todos Medical Ltd. announced positive results from a pre-specified interim analysis of 20 subjects from an ongoing 40-subject outpatient study evaluating the relationship between LymPro Test™ scores with amyloid PET imaging scores.
One problem facing researchers in Alzheimer’s disease is the lack of really good diagnostic tests. Earlier this year, Bill Gates, Jeff Bezos and MacKenzie Bezos teamed to donate over $20 million to the Diagnostics Accelerator, part of the Alzheimer’s Drug Discovery Foundation (ADDF).
Company recognized for its leadership in advancing blood-based tests to diagnose cancer
PRESS RELEASES